About E3 ubiquitin-protein ligase TRIM58
E3 ubiquitin-protein ligase TRIM58 (TRIM58) is a protein
from Homo sapiens identified by UniProt accession
Q8NG06, 486 residues long.
MolForge cross-references it against 0 known binders and
89 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase TRIM58 |
| UniProt accession | Q8NG06 |
| Gene | TRIM58 |
| Organism | Homo sapiens |
| Length | 486 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (89)
Diseases linked to this target (Open Targets).
- mean platelet volume · score 0.50
- reticulocyte count · score 0.46
- reticulocyte measurement · score 0.43
- Red cell distribution width · score 0.43
- mean corpuscular volume · score 0.40
- mean corpuscular hemoglobin concentration · score 0.40
- platelet count · score 0.40
- hemoglobin measurement · score 0.39
- mean reticulocyte volume · score 0.39
- erythrocyte count · score 0.38
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8NG06-F1 | alphafold | PREDICTED | 86.70 | — |
Amino-acid sequence (486 residues)
MAWAPPGERL REDARCPVCL DFLQEPVSVD CGHSFCLRCI SEFCEKSDGA QGGVYACPQC RGPFRPSGFR PNRQLAGLVE SVRRLGLGAG PGARRCARHG EDLSRFCEED EAALCWVCDA GPEHRTHRTA PLQEAAGSYQ VKLQMALELM RKELEDALTQ EANVGKKTVI WKEKVEMQRQ RFRLEFEKHR GFLAQEEQRQ LRRLEAEERA TLQRLRESKS RLVQQSKALK ELADELQERC QRPALGLLEG VRGVLSRSKA VTRLEAENIP MELKTACCIP GRRELLRKFQ VDVKLDPATA HPSLLLTADL RSVQDGEPWR DVPNNPERFD TWPCILGLQS FSSGRHYWEV LVGEGAEWGL GVCQDTLPRK GETTPSPENG VWALWLLKGN EYMVLASPSV PLLQLESPRC IGIFLDYEAG EISFYNVTDG SYIYTFNQLF SGLLRPYFFI CDATPLILPP TTIAGSGNWA SRDHLDPASD VRDDHL
Explore E3 ubiquitin-protein ligase TRIM58 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets